Managing multiple myeloma in 2023
The latest myeloma treatment advances from ASCO 2023 - MMRF
Tecvayli. Tecvayli was the first approved off-the-shelf BCMA-directed bispecific antibody for the treatment of patients with RRMM. The approval was ...
Multiple Myeloma in 2023 Ways: From Trials to Real Life - PMC
Forimtamig is a GPRC5DxCD3 T-cell-engaging bispecific antibody that has proved to be effective in RRMM with long-term treatment response. Results from a phase 1 ...
In the Fall 2023 edition, IMF Chief Medical Officer Dr. Joseph Mikhael highlights the approval of two new myeloma drugs. Those drugs, ELREXFIO™ and TALVEY™, ...
Multiple Myeloma: Improved Prognosis With the Latest Treatments
Bispecific antibody drug treatments · Bispecific antibodies are a relatively new class of drugs in multiple myeloma. · In October 2022, the FDA ...
Managing multiple myeloma in 2023 - Royal College of Pathologists
Professor Guy Pratt explores the challenges of managing multiple myeloma in today's world. Multiple myeloma has a poorly understood genetic origin.
2023 Mid-Year Science Update - International Myeloma Foundation
With the introduction and assessment of new testing methodologies, as well as multiple and very active new therapies, it is crystal clear that ...
Multiple myeloma - Diagnosis and treatment - Mayo Clinic
Treatments for myeloma · Targeted therapy. Targeted therapy uses medicines that attack specific chemicals in the cancer cells. · Immunotherapy.
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and ...
Standard risk patients need lenalidomide maintenance, while bortezomib plus lenalidomide maintenance is needed for high-risk myeloma. Management ...
Past, Present, and a Glance into the Future of Multiple Myeloma ...
In 2019, daratumumab, lenalidomide, and dexamethasone (DRd) treatment was approved in NDMM patients who are ineligible for transplant after phase III MAIA trial ...
FDA Approves Two New Treatments for Heavily Pretreated Multiple ...
Talquetamab and elranatamab are a form of targeted immunotherapy called bispecific antibodies and are the first ever in this class approved to ...
Drugs & Treatment by Stage - Multiple Myeloma Research Foundation
The standard of care for newly diagnosed multiple myeloma is called induction therapy, followed by an autologous stem cell transplant (if eligible) and ...
Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI
Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer ...
Guidelines Summary, Treatment, Management of Multiple Myeloma ...
A single autologous stem cell transplant is the preferred approach in transplant-eligible patients · Bortezomib/lenalidomide/dexamethasone ( ...
How I treat multiple myeloma in geriatric patients - ASH Publications
However, treatment outcomes have slowly improved in recent years. In the EMMY real-life cohort, 561 patients aged ≥80 years were enrolled between 2017 and 2019 ...
Multiple Myeloma Treatment & Management - Medscape Reference
In August 2023, the FDA granted accelerated approval to elranatamab (Elrexfio) for relapsed or refractory MM in adults who have received at ...
Motixafortide and Stem Cell Transplants for Multiple Myeloma - NCI
For people with multiple myeloma, treatment often includes high-dose chemotherapy to destroy cancerous blood cells, followed by a stem cell ...
A roadmap towards improving outcomes in multiple myeloma - Nature
The landscape of MM treatment is poised for transformation in 2024 and beyond. Embracing improved trial design, prioritizing patient-centric ...
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone ...
12, 2023) – Patients with newly diagnosed multiple myeloma (MM) who ... “With these results, [I expect] this treatment schedule will be the future ...
How Can Myeloma Outcomes Improve in 2024? - HealthTree
... 2023, myeloma specialists share treatment approaches from improving patient care in today's myeloma ... treatment options for multiple myeloma ...
Researchers discover innovative new treatment approach for ...
“The ability of multiple myeloma cells to escape the immune system is one factor underlying relapse that has gained increasing attention over ...